First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Pembrolizumab for head and neck cancer

Nivolumab extends survival for patients with the most common lung cancer

Pembrolizumab shows promising activity against head and neck cancer

Prostate cancer and pharmacokinetics: Expert discussion

New approaches to diffuse large B-cell lymphoma

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma